Drug delivery implants in the treatment of vitreous inflammation

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Wang, Jillian ^a   Jiang, Angela ^a   Joshi, Malav ^b   Christoforidis, John ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; LIPOSOME; NANOPARTICLE; POLYMER; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BIOMATERIAL; MONOCLONAL ANTIBODY;

ARTHRALGIA; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUSTAINED DRUG RELEASE; UVEITIS; VISUAL ACUITY; VITREOUS DISEASE; VITREOUS INFLAMMATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EYE; INFLAMMATION; PARTICLE SIZE; PATHOLOGY; PROSTHESES AND ORTHOSES; VITREOUS BODY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; EYE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; HUMANS; INFLAMMATION; PARTICLE SIZE; POLYMERS; PROSTHESES AND IMPLANTS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 84885571516     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/780634     Document Type: Review

References (76)

1. Duvvuri S., Majumdar S., Mitra A. K., Drug delivery to the retina: challenges and opportunities. Expert Opinion on Biological Therapy 2003 3 1 45 56 2-s2.0-0037319276 10.1517/14712598.3.1.45 (Pubitemid 36193650)
2. Christoforidis J. B., Chang S., Jiang A., Wang J., Cebulla C., Intravitreal devices for the treatment of vitreous inflammation. Mediators of Inflammation 2012 2012 8 126463 10.1155/2012/126463
3. Shah S. S., Denham L. V., Elison J. R., Bhattacharjee P. S., Clement C., Hug T., Hill J. M., Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Review of Ophthalmology 2010 5 1 75 93 10.1586/eop.09.70
4. Lee S. S., Hughes P., Ross A. D., Robinson M. R., Biodegradable implants for sustained drug release in the eye. Pharmaceutical Research 2010 27 10 2043 2053 2-s2.0-77957340876 10.1007/s11095-010-0159-x
5. Yasukawa T., Ogura Y., Medical devices for the treatment of eye diseases. Handbook of Experimental Pharmacology 2010 197 469 489 2-s2.0-77953248909 10.1007/978-3-642-00477-3-16
6. Sanborn G. E., Anand R., Torti R. E., Nightingale S. D., Cal S. X., Yates B., Ashton P., Smith T., Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Archives of Ophthalmology 1992 110 2 188 195 2-s2.0-0026516615
7. Martin D. F., Parks D. J., Mellow S. D., Ferris F. L., Walton R. C., Remaley N. A., Chew E. Y., Ashton P., Davis M. D., Nussenblatt R. B., Treatment of cytomegalovirus retinitis with an intraocular sustained- release ganciclovir implant: a randomized controlled clinical trial. Archives of Ophthalmology 1994 112 12 1531 1539 2-s2.0-0027937920 (Pubitemid 24373070)
8. Jabs D. A., Ahuja A., Natta M. V., Dunn J. P., Yeh S., Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2013 120 6 1262 1270 10.1016/j.ophtha.2012.11.023
9. Lim J. I., Wolitz R. A., Dowling A. H., Bloom H. R., Irvine A. R., Schwartz D. M., Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. American Journal of Ophthalmology 1999 127 3 288 293 2-s2.0-0033104581 10.1016/S0002-9394(98)00443-7 (Pubitemid 29128126)
10. Shane T. S., Martin D. F., Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. American Journal of Ophthalmology 2003 136 4 649 654 2-s2.0-0141793765 10.1016/S0002-9394(03)00333-7 (Pubitemid 37153179)
11. Pearson P. A., Comstock T. L., Ip M., Callanan D., Morse L. S., Ashton P., Levy B., Mann E. S., Eliott D., Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011 118 8 1580 1587 2-s2.0-79961044911 10.1016/j.ophtha.2011.02.048
12. Jain N., Stinnett S. S., Jaffe G. J., Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012 119 1 132 137 2-s2.0-84855324053 10.1016/j.ophtha.2011.06.019
13. Callanan D. G., Jaffe G. J., Martin D. F., Pearson P. A., Comstock T. L., Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Archives of Ophthalmology 2008 126 9 1191 1201 2-s2.0-51649093336 10.1001/archopht.126.9.1191
14. Jaffe G. J., Martin D., Callanan D., Pearson P. A., Levy B., Comstock T., Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 113 6 1020 1027 2-s2.0-33646925637 10.1016/j.ophtha.2006.02. 021 (Pubitemid 43795240)
15. Pavesio C., Zierhut M., Bairi K., Comstock T. L., Usner D. W., Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010 117 3 567 575 2-s2.0-77049097118 10.1016/j.ophtha.2009.11.027
16. Kempen J. H., Altaweel M. M., Holbrook J. T., Jabs D. A., Louis T. A., Sugar E. A., Thorne J. E., Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011 118 10 1916 1926 2-s2.0-80053594211 10.1016/j.ophtha.2011.07.027
17. Nicholson B. P., Singh R. P., Sears J. E., Lowder C. Y., Kaiser P. K., Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. American Journal of Ophthalmology 2012 154 969 973
18. Campochiaro P. A., Brown D. M., Pearson A., Chen S., Boyer D., Ruiz-Moreno J., Garretson B., Gupta A., Hariprasad S. M., Bailey C., Reichel E., Soubrane G., Kapik B., Billman K., Kane F. E., Green K., Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012 119 10 2125 2132
19. Dugel P. U., Eliott D., Cantrill H. L., Mahmoud T., Avery R., Erickson S. R., I-vation TM TA: 24-month clinical results of the phase I safety and preliminary efficacy study. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting 2009 Fort Lauderdale, Fla, USA
20. Clinicaltrials.gov, A Study of MK0140 in Diabetic Patients with Macular Edema. http://clinicaltrials.gov/ct2/archive/NCT00692614
21. Biro A., Good early results seen with anti-VEGF refillable port delivery system. January 2013, http://www.healio.com/ophthalmology/retina-vitreous/news/ print/osn-retina/{4df622f8-54f7-4895-a182-a1fbbe6902b4}/good-early-results-seen- with-anti-vegf-refillable-port-delivery-system
22. Edelman J. L., Differentiating intraocular glucocorticoids. Ophthalmologica 2010 224 1 25 30 2-s2.0-77955801287 10.1159/000315158
23. Lowder C., Belfort R. Jr., Lightman S., Foster C. S., Robinson M. R., Schiffman R. M., Li X.-Y., Cui H., Whitcup S. M., Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology 2011 129 5 545 553 2-s2.0-79952947252 10.1001/archophthalmol.2010. 339
24. Hunter R. S., Lobo A.-M., Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology 2011 5 1 1612 1621 2-s2.0-81155135095
25. Haller J. A., Bandello F., Belfort R. Jr., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y.-H., Jacques M.-L., Jiao J., Li X.-Y., Whitcup S. M., Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010 117 6 1134 1146 2-s2.0-77952882990 10.1016/j.ophtha.2010.03.032
26. Haller J. A., Bandello F., Belfort R. Jr., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y. H., Jiao J., Li X.-Y., Whitcup S. M., Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 2011 118 12 2453 2460 2-s2.0-80052857441 10.1016/j.ophtha.2011.05. 014
27. Bezatis A., Spital G., Hohn F., Maier M., Clemens C. R., Wachtlin J., Lehmann F., Hattenbach L. O., Feltfen N., Meyer C. H., Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO study. Acta Ophthalmologica 2013 91 5 e340 e347 10.1111/aos.12020
28. Clinicaltrials.gov, Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C). http://clinicaltrials.gov/ct2/show/ NCT01396083
29. Clinicaltrials.gov, Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (COMRADE-B). http://clinicaltrials.gov/ct2/show/ NCT01396057
30. Clinicaltrials.gov, Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (ORION). http://clinicaltrials.gov/ct2/show/ NCT01827722
31. Adan A., Pelegrin L., Rey A., Llorenc V., Mesquida M., Molins B., Rios J., Keller J., Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 2013 33 7 1435 1440 10.1097/IAE.0b013e31827e247b
32. Bailif S., Maschi C., Gastaud P., Caujolle J. P., Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma. Retina 2013 10.1097/IAE.0b013e31829234fa
33. Srour M., Quergues G., Leveziel N., Zerbib J., Tilleul J., Boulanger-Scemama E., Souied E. H., Intravitreal dexamethasone implan (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefe's Archive for Clinical and Experimental Ophthalmology 2013 251 6 1501 1506 10.1007/s00417-012-2249-4
34. Tan D. T. H., Chee S.-P., Lim L., Lim A. S. M., Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 1999 106 2 223 231 2-s2.0-0033510684 (Pubitemid 30191616)
35. Tan D. T. H., Chee S.-P., Lim L., Theng J., van Ede M., Randomized clinical trial of surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two surodex in the eye. Ophthalmology 2001 108 12 2172 2181 2-s2.0-0035180823 10.1016/S0161-6420(01)00839-9 (Pubitemid 33096927)
36. Wadood A. C., Armbrecht A. M., Aspinall P. A., Dhillon B., Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. Journal of Cataract and Refractive Surgery 2004 30 4 761 768 2-s2.0-16544369509 10.1016/j.jcrs.2003.08.028 (Pubitemid 38501468)
37. Inc I., Verisome. http://iconbioscience.com/verisome
38. Fung A. E., One-year safety and efficacy of an injectable, sustained-delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion. Angiogenesis 2010 Miami, Fla, USA
39. Lim J. I., Niec M., Hung D., Wong V., A pilot study of combination therapy for neovascular AMD using a single injection of liquid sustained release intravitreal triamcinolone acetonide and intravitreal ranibizunab as needed. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting 2012 Fort Lauderdale, Fla, USA
40. He Y., Wang J.-C., Liu Y.-L., Ma Z.-Z., Zhu X.-A., Zhang Q., Therapeutic and toxicological evaluations of cyclosporine A microspheres as a treatment vehicle for uveitis in rabbits. Journal of Ocular Pharmacology and Therapeutics 2006 22 2 121 131 2-s2.0-33646684466 10.1089/jop.2006.22.121 (Pubitemid 43742948)
41. Beeley N. R. F., Rossi J. V., Mello-Filho P. A. A., Mahmoud M. I., Fujii G. Y., De Juan E. Jr., Varner S. E., Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. Journal of Biomedical Materials Research A 2005 73 4 437 444 2-s2.0-20344367783 10.1002/jbm.a.30294 (Pubitemid 40791391)
42. Gilger B. C., Wilkie D. A., Clode A. B., McMullen R. J., Utter M. E., Komaromy A. M., Brooks D. E., Salmon J. H., Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Veterinary Ophthalmology 2010 13 5 294 300 2-s2.0-77956295513 10.1111/j.1463-5224.2010.00807.x
43. Nishi O., Nishi K., Morita T., Tada Y., Shirasawa E., Sakanishi K., Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification. Journal of Cataract and Refractive Surgery 1996 22 supplement 1 806 810 2-s2.0-0030321390
44. Badawi A. A., El-Laithy H. M., El Qidra R. K., El Mofty H., El Dally M., Chitosan based nanocarriers for indomethacin ocular delivery. Archives of Pharmacal Research 2008 31 8 1040 1049 2-s2.0-51849112416 10.1007/s12272-001- 1266-6
45. Balasubramaniam J., Kumar M. T., Pandit J. K., Kant S., Gellan-based scleral implants of indomethacin: in vitro and in vivo evaluation. Drug Delivery 2004 11 6 371 379 2-s2.0-9644274085 10.1080/10717540490884787 (Pubitemid 39578596)
46. Kreuter J., Nanoparticles. Encyclopedia of Pharmaceutical Technology 1994 New York, NY, USA Marcel Dekker 165 190
47. Mufamadi M. S., Pillay V., Choonara Y. E., Du Toit L. C., Modi G., Naidoo D., Ndesendo V. M., A review on composite liposomal technologies for specialized drug delivery. Journal of Drug Delivery 2011 2011 19 10.1155/2011/939851 939851
48. Bochot A., Fattal E., Liposomes for intravitreal drug delivery: a state of the art. Journal of Controlled Release 2012 161 2 628 634 2-s2.0-84856779304 10.1016/j.jconrel.2012.01.019
49. Zimmer A., Kreuter J., Microspheres and nanoparticles used in ocular delivery systems. Advanced Drug Delivery Reviews 1995 16 1 61 73 2-s2.0-0029347475 10.1016/0169-409X(95)00017-2
50. Ophthalmics V., Visudyne. 2013, http://visudyne.com/
51. Kuno N., Fujii S., Recent advances in ocular drug delivery systems. Polymers 2011 3 1 193 221 2-s2.0-79851469220 10.3390/polym3010193
52. Barza M., Baum J., Tremblay C., Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. American Journal of Ophthalmology 1985 100 2 259 263 2-s2.0-0022000969 (Pubitemid 15240586)
53. Zeng S., Hu C., Wei H., Lu Y., Zhang Y., Yang J., Yun G., Zou W., Song B., Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology 1993 100 11 1640 1644 2-s2.0-0027366709 (Pubitemid 23335927)
54. Cannon J. P., Fiscella R., Pattharachayakul S., Garey K. W., De Alba F., Piscitelli S., Edward D. P., Danziger L. H., Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Investigative Ophthalmology and Visual Science 2003 44 5 2112 2117 2-s2.0-0037406802 10.1167/iovs.02-1020 (Pubitemid 36520306)
55. Abrishami M., Zarei-Ghanavati S., Soroush D., Rouhbakhsh M. R., Jaafari B., Malaekeh-Nikouei B., Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009 29 5 699 703 10.1097/IAE.0b013e3181a2f42a
56. Kuppermann B. D., Assil K. K., Vuong C., Besen G., Wiley C. A., De Clercq E., Bergeron-Lynn G., Connor J. D., Pursley M., Munguia D., Freeman W. R., Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. Journal of Infectious Diseases 1996 173 1 18 23 2-s2.0-19144367116 (Pubitemid 26006798)
57. Diaz-Llopis M., Martos M. J., Espana E., Cervera M., Ofelia Vila A., Navea A., Molina F. J., Romero F. J., Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Experimental toxicity and pharmacokinetics, and clinical trial. Documenta Ophthalmologica 1992 82 4 297 305 2-s2.0-0026974894 (Pubitemid 23179158)
58. Wiechens B., Krausse R., Grammer J. B., Neumann D., Pleyer U., Duncker G. I. W., Clearance of liposome-incorporated ciprofloxacin after intravitreal injection in rabbit eyes. Klinische Monatsblatter für Augenheilkunde 1998 213 5 284 292 2-s2.0-0032217202 (Pubitemid 29001094)
59. Fiscella R., Peyman G. A., Fishman P. H., Duration of therapeutic levels of intravitreally injected liposome-encapsulated clindamycin in the rabbit. Canadian Journal of Ophthalmology 1987 22 6 307 309 2-s2.0-0023627422 (Pubitemid 17163898)
60. Fishman P. H., Peyman G. A., Lesar T., Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Investigative Ophthalmology and Visual Science 1986 27 7 1103 1106 2-s2.0-0022532408 (Pubitemid 16062047)
61. Kim E. K., Kim H. B., Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits. Yonsei Medical Journal 1990 31 4 308 314 2-s2.0-0025679393
62. de Jong W. H., Borm P. J. A., Drug delivery and nanoparticles: applications and hazards. International Journal of Nanomedicine 2008 3 2 133 149 2-s2.0-61349139614 (Pubitemid 352042401)
63. Shelke N. B., Kadam R., Tyagi P., Rao V., Kompella U., Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases. Drug Delivery and Translational Research 2011 1 1 76 90 10.1007/s13346-010-0009-8
64. Cardillo J. A., Souza-Filho A. A., Oliveira A. G., Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Archivos de la Sociedad Española de Oftalmología 2006 81 12 675 682 2-s2.0-34248214266
65. Moritera T., Ogura Y., Yoshimura N., Honda Y., Wada R., Hyon S.-H., Ikada Y., Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science 1992 33 11 3125 3130 2-s2.0-0026669865
66. Carrasquillo K. G., Ricker J. A., Rigas I. K., Miller J. W., Gragoudas E. S., Adamis A. P., Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Investigative Ophthalmology and Visual Science 2003 44 1 290 299 2-s2.0-0037251511 10.1167/iovs.01-1156 (Pubitemid 36134287)
67. He Y., Liu Y., Liu Y., Wang J., Zhang X., Lu W., Ma Z., Zhu X., Zhang Q., Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. Investigative Ophthalmology and Visual Science 2006 47 9 3983 3988 2-s2.0-33749124756 10.1167/iovs.05-1373 (Pubitemid 46044315)
68. Genta I., Conti B., Perugini P., Pavanetto F., Spadaro A., Puglisi G., Bioadhesive microspheres for ophthalmic administration of acyclovir. Journal of Pharmacy and Pharmacology 1997 49 8 737 742 2-s2.0-0030931036 (Pubitemid 27386891)
69. de Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.-C., Garcia E., Couvreur P., Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. European Journal of Immunology 2004 34 12 3702 3712 2-s2.0-10944223807 10.1002/eji.200425022 (Pubitemid 40012188)
70. Sabzevari A., Adibkia K., Hashemi H., Hedayatfar A., Mohsenzadeh N., Atyabi F., Ghahremani M. H., Dinarvand R., Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics 2013 84 1 63 71 10.1016/j.ejpb.2012.12.010
71. El-Samaligy M. S., Rojanasakul Y., Charlton J. F., Weinstein G. W., Lim J. K., Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye. Drug Delivery 1996 3 2 93 97 2-s2.0-0029745680 (Pubitemid 26281549)
72. Gehlbach P., Demetriades A. M., Yamamoto S., Deering T., Duh E. J., Yang H. S., Cingolani C., Lai H., Wei L., Campochiaro P. A., Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Therapy 2003 10 8 637 646 2-s2.0-0038742908 10.1038/sj.gt.3301931 (Pubitemid 36553609)
73. Saishin Y., Silva R. L., Saishin Y., Kachi S., Aslam S., Yuan Y. G., Lai H., Carrion M., Harris B., Hamilton M., Wei L., Campochiaro P. A., Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Human Gene Therapy 2005 16 4 473 478 2-s2.0-20844447893 10.1089/hum.2005.16.473 (Pubitemid 40647144)
74. Campochiaro P. A., Nguyen Q. D., Shah S. M., Klein M. L., Holz E., Frank R. N., Saperstein D. A., Gupta A., Stout J. T., Macko J., DiBartolomeo R., Wei L. L., Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Human Gene Therapy 2006 17 2 167 176 2-s2.0-32944481724 10.1089/hum.2006.17.167 (Pubitemid 43262032)
75. Li F., Hurley B., Liu Y., Leonard B., Griffith M., Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmology Journal 2012 6 54 58 10.2174/ 1874364101206010054
76. Clinicaltrials.gov, Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. http://clinicaltrials.gov/ct2/show/NCT01523314